The Global Rheumatoid Arthritis Market Forecasts to 2012

Questions: Discounts, Updates etc.

Pages: 112

Price (Single): £1,499

Price (Departmental): £2,999

Price (Company): £4,999

Publication Date: 2007-03-09

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

In a market believed to approach 5 million people in the leading pharma markets, the market for rheumatic anti-inflammatory drugs is both profitable and set to increase due to new launches. The annual revenue to Q3 2006, from the main prescription anti-inflammatory drugs worldwide, including non steroidal anti-inflammatories (NSAIDs), anti-rheumatic corticosteroid combinations and specific anti-rheumatics was in the order of $16bn worldwide. This market cannot be ignored. A life-long disease with no cure, the disease has been targeted greatly by pharma companies with the launch of novel targeted biologic therapies. However this has meant that the market for severe RA has become crowded - but is it saturated?

Historically management of RA has relied on symptomatic treatment with a variety of anti-inflammatories, toxic immunosuppressants and corticosteroids. None of these treatments, however, had the ability to prevent underlying disease progression. The advent of a series of new biological monoclonal antibodies to treat RA has changed this situation dramatically. There is now a real possibility of actually modifying the progression of chronic disease, decreasing disability levels and enabling more normal lifestyles for RA patients.

These new monoclonal antibodies specifically target the early pathways of inflammation preventing damage and abrogating the onset of the vicious cycle of inflammation and tissue destruction. The first new biological drugs for RA are already on the market and have met with outstanding clinical success. There are now several important regulatory issues concerning the older biological drugs as patents are expiring and the biosimilar race by generic companies gets underway. There is also a strong pipeline of new drugs in development which could make exciting and important breakthroughs.

Questions however remain, that this new report will answer for you, such as: Will the current monoclonal blockbuster used to treat RA continue to grow?  How dark is the future for coxibs and as a drug class are they doomed? What are the hottest research drugs in the pipeline? Will the manufacture and marketing of biosimilars overcome regulatory hurdles? 

The main treatment categories discussed in the report include:

With new expensive biological drugs targeted at the US, Europe and Japan, generating revenues of $9450m in the last 12 months, visiongain believe that the growth of the disease within developing nations will see cheaper alternatives increase revenue also.

With global market analysis and forecast right through to 2012, the report tackles a SWOT breakdown affecting the use of NSAIDs and biologicals. Targeted  immunology relating to RA and sets out the targets for future research. This is taken up in the pipelines chapter which deals with the pipeline. These two chapters have been designed to allow the reader to get a good summary of what is opening up in the future treatment for RA. Visiongain sees a continuing shift towards biological treatment of RA and the treatment options are expanding. Biologicals provide greater opportunity to modulate disease progression and alleviate the chronic cycle of inflammation and pathology. Leading biological companies have strong pipelines and time will determine the future potential of the next generation of anti-inflammatory drugs. In the meantime, the use of traditional mainstay drugs will continue until newer agents have a proven record of safety and efficacy. The early signs with the novel therapies look very promising.

- Exclusive information of market shares and revenues till 2012 for all of the major drugs have been forecast -

Included in this report:
This report includes an up-to-date, analysis of RA including the current market and possible future developments. The following important issues are covered in detail:

Methodology

The information contained in this report is from primary industry sources. This includes one-on-one interviews with companies, with governmental bodies and academic institutions. Analysis has also been drawn from company reports, whether annual financial returns or white papers. The author of this report has dealt with over 50+ companies and industry contacts to assist on the production of this report.

Table of Contents

 

  • List of Tables

    •  

     

  • List of Figures

    •  

    Other users found this report page using the following search terms: rheumatoid arthritis autoimmune arthritis market rheumatoid global india sales lornoxicam ra prevalence patent

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.